| | Authors | Year | Study design | Intervention | Sampling | Age (year) | Jadad scale | Follow-up |
| | Zeng, R.P. | 2017 | RCT | A | 125 | 65.1 ± 7.1 | 4 | 1 mo, 3 mo, 6 mo | | B | 125 | 64.8 ± 6.8 |
| | Guo, X. | 2020 | RCT | IVC (3 injections, no mention of dose) + B | 34 | 61.8 ± 2.4 | 4 | 1 wk, 1 mo, 3 mo | | B | 34 | 62.7 ± 2.3 |
| | Li, B.J. | 2017 | RCT | IVC (2 injections of 0.05 mL) + B | 20 | 59.07 ± 5.12 | 4 | 45 d, 3 mo | | B | 20 | 58.47 ± 4.29 |
| | Li, B.Y. | 2020 | RCT | A | 60 | 45.7 ± 7.3 | 3 | 15 d | | B | 60 | 46.1 ± 6.6 |
| | Li, Y,Y. | 2021 | RCT | A | 58 | 64.39 ± 5.62 | 4 | 1 mo, 3 mo, 6 mo | | B | 58 | 63.19 ± 6.12 |
| | Li, Y.L. | 2019 | RCT | IVC (3 injections of 0.05 mL) + B | 713 | 49.6 ± 12.8 | 4 | 1 wk, 1 mo, 3 mo, 6 mo | | B | 713 | 48.3 ± 11.7 |
| | Nulahou | 2019 | RCT | A | 46 | 63.45 ± 6.63 | 4 | 3 mo | | B | 46 | 62.10 ± 5.39 |
| | Ran, Z.L. | 2020 | RCT | Single IVC (no mention of dose) + B | 40 | 60.95 ± 9.24 | 3 | 1 mo, 3 mo, 6 mo | | B | 40 | 60.31 ± 8.37 |
| | Tang, J. | 2017 | RCT | A | 60 | 51.56 ± 1.48 | 3 | 1 mo, 2 mo, 3 mo | | B | 60 | 52.64 ± 1.58 |
| | Yang, L. | 2017 | RCT | single IVC (no mention of dose) + B | 30 | 62.61 ± 6.59 | 4 | 3 mo, 6 mo | | B | 30 | 63.14 ± 6.79 |
| | Yang, Z. | 2017 | RCT | IVC (3 injections of 0.05 mL) + B | 54 | 51.68 ± 10.02 | 4 | 1 mo, 2 mo, 3 mo | | B | 54 | 51.60 ± 11.48 |
| | Chen, R. | 2019 | RCT | IVC (3 injections of 0.05 mL) + B | 60 | 56.72 ± 6.88 | 4 | 1 mo, 3 mo | | B | 60 | 56.27 ± 6.82 |
|
|
